Replacement Sheet U.S. Serial No. 09/766,344 Attorney Docket No.: 11068-033-999 Filing Date: January 19, 2001


Title: Means and Methods For Monitoring Protease Inhibitor Antiretroviral Therapy and Guiding Therapeutic Decisions in the Treatment of HIV/AIDS

Inventors: Parkin & Ziermann



1/30

PhenoSenseTM HIV Resistance Test Vector



BEST AVAILABLE COPY

PhenoSenseTM Schematic Diagram

Title: Means and Methods For Monitoring Protease Inhibitor Antiretroviral Therapy and Guiding Therapeutic Decisions in the Treatment of HIV/AIDS

Inventors: Parkin & Ziermann Filing Date: January 19, 2001





Fig. 2

Title: Means and Methods For Monitoring Protease Inhibitor Antiretroviral Therapy and Guiding Therapeutic Decisions in the Treatment of HIV/AIDS Inventors: Parkin & Ziermann

Filing Date: January 19, 2001




Title: Means and Methods For Monitoring Protease Inhibitor Antiretroviral Therapy and Guiding Therapeutic Decisions in the Treatment of HIV/AIDS

Inventors: Parkin & Ziermann Filing Date: January 19, 2001

4/30




Replacement Sheet U.S. Serial No. 09/766,344 Attorney Docket No.: 11068-033-999



Title: Means and Methods For Monitoring Protease Inhibitor Antiretroviral Therapy and Guiding Therapeutic Decisions in the Treatment of HIV/AIDS

Inventors: Parkin & Ziermann Filing Date: January 19, 2001



Title: Means and Methods For Monitoring Protease Inhibitor Antiretroviral Therapy and Guiding Therapeutic Decisions in the Treatment of HIV/AIDS

Inventors: Parkin & Ziermann Filing Date: January 19, 2001




Fig. 4A




Fig. 4B

Title: Means and Methods For Monitoring Protease Inhibitor Antiretroviral Therapy and Guiding Therapeutic Decisions in the Treatment of HIV/AIDS

Inventors: Parkin & Ziermann Filing Date: January 19, 2001




Fig. 4C





Fig. 4D

Title: Means and Methods For Monitoring Protease Inhibitor Antiretroviral Therapy and Guiding Therapeutic Decisions in the Treatment of HIV/AIDS

Inventors: Parkin & Ziermann Filing Date: January 19, 2001



Title: Means and Methods For Monitoring Protease Inhibitor Antiretroviral Therapy and Guiding Therapeutic Decisions in the Treatment of HIV/AIDS

Inventors: Parkin & Ziermann Filing Date: January 19, 2001

Replacement Sheet

U.S. Serial No. 09/766,344

Attorney Docket No.: 11068-033-999




Fig. 5A




Fig. 5B

Title: Means and Methods For Monitoring Protease Inhibitor Antiretroviral Therapy and Guiding Therapeutic Decisions in the Treatment of HIV/AIDS


Inventors: Parkin & Ziermann Filing Date: January 19, 2001

Replacement Sheet

U.S. Serial No. 09/766,344

Attorney Docket No.: 11068-033-999









Fig. 5D


Title: Means and Methods For Monitoring Protease Inhibitor Antiretroviral Therapy and Guiding Therapeutic Decisions in the Treatment of HIV/AIDS

Inventors: Parkin & Ziermann Filing Date: January 19, 2001



Title: Means and Methods For Monitoring Protease Inhibitor Antiretroviral Therapy and Guiding Therapeutic Decisions in the Treatment of HIV/AIDS

Inventors: Parkin & Ziermann Filing Date: January 19, 2001



Title: Means and Methods For Monitoring Protease Inhibitor Antiretroviral Therapy and Guiding Therapeutic Decisions in the Treatment of HIV/AIDS

Inventors: Parkin & Ziermann Filing Date: January 19, 2001





Fig. 6B


Title: Means and Methods For Monitoring Protease Inhibitor Antiretroviral Therapy and Guiding Therapeutic Decisions in the Treatment of HIV/AIDS


Inventors: Parkin & Ziermann Filing Date: January 19, 2001



Title: Means and Methods For Monitoring Protease Inhibitor Antiretroviral Therapy and Guiding Therapeutic Decisions in the Treatment of HIV/AIDS Inventors: Parkin & Ziermann

Filing Date: January 19, 2001






A = Ala C = Cys E = Glu Q = Gln S = Ser T = Thr

Fig. 6D

Title: Means and Methods For Monitoring Protease Inhibitor Antiretroviral Therapy and Guiding Therapeutic Decisions in the Treatment of HIV/AIDS

Inventors: Parkin & Ziermann Filing Date: January 19, 2001



Title: Means and Methods For Monitoring Protease Inhibitor Antiretroviral Therapy and Guiding Therapeutic Decisions in the Treatment of HIV/AIDS Inventors: Parkin & Ziermann

Filing Date: January 19, 2001





Fig. 6F


Title: Means and Methods For Monitoring Protease Inhibitor Antiretroviral Therapy and Guiding Therapeutic Decisions in the Treatment of HIV/AIDS

Inventors: Parkin & Ziermann Filing Date: January 19, 2001



Title: Means and Methods For Monitoring Protease Inhibitor Antiretroviral Therapy and Guiding Therapeutic Decisions in the Treatment of HIV/AIDS

Inventors: Parkin & Ziermann Filing Date: January 19, 2001



Title: Means and Methods For Monitoring Protease Inhibitor Antiretroviral Therapy and Guiding Therapeutic Decisions in the Treatment of HIV/AIDS Inventors: Parkin & Ziermann

Filing Date: January 19, 2001

20/30

Low Replication Capacity is Associated with High Numbers of Mutations in Protease and L90M





Fig. 6I

Title: Means and Methods For Monitoring Protease Inhibitor Antiretroviral Therapy and Guiding Therapeutic Decisions in the Treatment of HIV/AIDS

Inventors: Parkin & Ziermann Filing Date: January 19, 2001




Title: Means and Methods For Monitoring Protease Inhibitor Antiretroviral Therapy and Guiding Therapeutic Decisions in the Treatment of HIV/AIDS

Inventors: Parkin & Ziermann Filing Date: January 19, 2001

22/30

Replacement Sheet U.S. Serial No. 09/766,344 Attorney Docket No.: 11068-033-999




Title: Means and Methods For Monitoring Protease Inhibitor Antiretroviral Therapy and Guiding Therapeutic Decisions in the Treatment of HIV/AIDS

Inventors: Parkin & Ziermann Filing Date: January 19, 2001

Replacement Sheet

U.S. Serial No. 09/766,344

Attorney Docket No.: 11068-033-999



Title: Means and Methods For Monitoring Protease Inhibitor Antiretroviral Therapy and Guiding Therapeutic Decisions in the Treatment of HIV/AIDS Inventors: Parkin & Ziermann

Filing Date: January 19, 2001

24/30


Patient Virus Reversion to Drug Susceptibility After Treatment Interruption

RABC MVP DLV RFV SQV 3 19 >300 48 115 85 14 >300 76 134 95 15 >300 76 142 89 15 >300 94 174 59 17 >300 94 174 59 18 >300 94 174 59 19 >300 93 168 89 12 >300 89 154 85 5.0 22 15 10 1.8 1.3 1.7 2.0 1.6 0.9 1 1.2 0.8 1.1 0.9 1.0 1 1.2 0.8 1.1 0.9 1.0 1			NRTI				NNRTI				٦		
ay 0 3.7 >1000 2.8 19 >300 68 115 85 4.5 >100 3.3 20 >300 78 134 95 5.8 >100 3.2 14 >300 75 142 89 6.5 >100 2.7 15 >300 94 174 59 6.3 >100 3.0 17 >300 76 119 59 6.4 >100 3.0 17 >300 76 119 59 5.0 >100 2.8 19 >300 93 168 89 5.0 >100 2.8 19 >300 93 168 89 5.0 >10 4.1 12 >300 93 168 89 5.0 >1.5 1.9 >300 22 15 10 1.8 1.5 1.7 1.1 1.1 1.2 1.2 1.2	WEEK	AZT	3TC		ABC	MAD	DLV	EFV	Ads	rov	RTV	MEV	S
4.5 >100 3.3 20 >300 76 134 95 5.8 >100 3.2 14 >300 75 142 89 6.5 >100 2.7 15 >300 96 183 59 6.3 >100 3.1 15 >300 94 174 59 6.4 >100 3.0 17 >300 76 119 59 5.0 >100 2.8 19 >300 76 119 59 9.1 >100 4.1 12 >300 93 168 89 2.8 8.1 1.9 5.0 22 15 1.8 1.8 1.5 1.7 1.1 1.3 1.7 2.0 1.6 0.9 1.0 0.9 1.2 1.0 1.2 0.8 1.1 0.9 1.0 0.9 0.9	day 0	3.7	>100	2.8	62	>300	88	115	85	72	73	74	16
6.5 >100 3.2 14 >300 75 142 89 6.5 >100 2.7 15 >300 96 183 59 6.4 >100 3.1 15 >300 94 174 59 6.4 >100 3.0 17 >300 76 119 59 5.0 >100 2.8 19 >300 76 119 59 9.1 >100 4.1 12 >300 89 154 85 2.8 8.1 1.9 5.0 22 15 10 1.8 1.5 1.7 1.1 1.1 1.2 0.8 1.1 0.9 1.0 0.9 1.2 1.0 1.2 0.8 1.1 0.9 1.0 0.9 1.3 0.8 1.2 0.5 1.0 0.8 0.8	_	4.5	>100	3.3	20	>300	7.8	134	95	74	53	80	21
6.5 >100 2.7 15 >300 96 183 59 6.4 >100 3.1 15 >300 94 174 59 6.4 >100 3.0 17 >300 76 119 59 5.0 >100 2.8 19 >300 93 168 89 59 2.8 8.1 12 >300 89 154 85 3.8 8.1 1.9 5.0 22 15 10 1.8 1.5 1.7 1.1 1.3 1.7 2.0 1.6 0.9 1.0 0.9 1.2 1.0 1.2 0.8 1.1 0.9 1.0 0.9 0.9 0.8 1.3 0.8 1.2 0.9	2	5.8	>100	3.2	14	>300	75	142	89	22	49	59	67
6.4 >100 3.1 15 >300 94 174 59 6.4 >100 3.0 17 >300 76 119 59 5.0 >100 2.8 19 >300 93 168 89 9.1 >100 4.1 12 >300 89 154 85 2.8 8.1 1.9 5.0 22 15 10 1.8 1.5 1.7 1.1 1.3 1.7 2.0 1.6 0.9 0.9 1.2 1.0 1.2 0.8 1.1 0.9 1.0 0.8 1.3 0.8 1.2 0.5 1.0 0.8 0.8	3	6.5	>100	2.7	15	>300	96	183	59	75	52	150	15
6.4 >100 3.0 17 >300 76 119 59 5.0 >100 2.8 19 >300 93 168 89 9.1 >100 4.1 12 >300 89 154 85 2.8 8.1 1.9 5.0 22 15 10 1.8 1.5 1.7 1.1 1.3 1.7 2.0 1.6 0.9 0.9 1.2 1.0 1.2 0.8 1.1 0.9 1.0 0.8 1.3 0.8 1.2 0.5 1.0 0.8 0.8	4	6.3	>100	3.1	1.5	>300	94	174	59	89	20	64	15
5.0 >100 2.8 19 >300 93 168 89 2.8 8.1 12 >300 89 154 85 1.5 8.1 1.9 5.0 22 15 10 1.8 1.5 1.7 1.1 1.3 1.7 2.0 1.6 0.9 0.9 1.2 1.2 0.8 1.1 0.9 1.0 0.8 1.3 0.8 1.2 0.5 1.0 0.8 0.8 0.7 1.1 1.0 0.6 0.8 1.1 0.9 0.8	5	6.4	>100	3.0	17	>300	76	119	59	99	25	36	10
9.1 >100 4.1 12 >300 89 154 85 2.8 8.1 1.9 5.0 22 15 10 1.8 1.5 1.7 1.1 1.3 1.7 2.0 1.6 0.9 0.9 1.2 1.2 0.8 1.1 0.9 1.0 0.8 1.3 0.8 1.2 0.5 1.0 0.8 0.8 0.7 1.1 1.0 0.6 0.8 1.1 0.9 0.8	9	5.0	>100	2.8	19	>300	93	168	68	39	80	4.0	18
2.8 8.1 1.9 5.0 22 15 10 1.8 1.5 1.7 1.1 1.3 1.7 2.0 1.6 0.9 0.9 1.2 1.0 1.2 0.8 1.1 0.9 1.0 0.8 1.3 0.8 1.2 0.5 1.0 0.8 0.8 0.7 1.1 1.0 0.6 0.6 0.6 0.6 0.6	7	9.1	>100	4.1	12	>300	68	154	85	7.8	23	53	9
1.5 1.7 1.1 1.3 1.7 2.0 1.6 0.9 0.9 1.2 1.0 1.2 0.8 1.1 0.9 1.0 0.8 1.3 0.8 1.2 0.5 1.0 0.8 0.8 0.7 1.1 1.0 0.6 0.8 1.1 0.0	6	2.8	8.1	1.9		22	15	10	1.8	i.	4 7	0 4	0
0.9 1.2 1.0 1.2 0.8 1.1 0.9 1.0 1 0.8 1.3 0.8 1.2 0.5 1.0 0.8 0.8 0 0.7 1.1 1.0 0.6 0.8 1.3 0.6	10	1.5	1.7	1.1	F. 7	1.7	2.0	1.6	6 0	7			9 9
0.8 1.3 0.8 1.2 0.5 1.0 0.8 0.8 0.7 1.1 1.0 0.6 0.8 1.3 0.9 0.5	11	6.0	1.2	1.0	1.2	9.0			1			0.4	• •
0.7 1.1 1.0 0.6 0.8 1.1 0.0		0.8	1.3	8.0	7	0.5	1			8 0	1 0		9 0
		0.7	1.1	1.0	9.0	0.8						+ • •	9

Fig. 6M

Title: Means and Methods For Monitoring Protease Inhibitor Antiretroviral Therapy and Guiding Therapeutic Decisions in the Treatment of HIV/AIDS Inventors: Parkin & Ziermann

Filing Date: January 19, 2001




Title: Means and Methods For Monitoring Protease Inhibitor Antiretroviral Therapy and Guiding Therapeutic Decisions in the Treatment of HIV/AIDS

Inventors: Parkin & Ziermann Filing Date: January 19, 2001

Replacement Sheet

U.S. Serial No. 09/766,344

Attorney Docket No.: 11068-033-999



Title: Means and Methods For Monitoring Protease Inhibitor Antiretroviral Therapy and Guiding Therapeutic Decisions in the Treatment of HIV/AIDS Inventors: Parkin & Ziermann

Filing Date: January 19, 2001

27/30 .




Fig. 6P

Title: Means and Methods For Monitoring Protease Inhibitor Antiretroviral Therapy and Guiding Therapeutic Decisions in the Treatment of HIV/AIDS

Inventors: Parkin & Ziermann Filing Date: January 19, 2001




Fig. 6Q

Title: Means and Methods For Monitoring Protease Inhibitor Antiretroviral Therapy and Guiding Therapeutic Decisions in the Treatment of HIV/AIDS


Inventors: Parkin & Ziermann Filing Date: January 19, 2001

29/30

Replacement Sheet

U.S. Serial No. 09/766,344

Attorney Docket No.: 11068-033-999



Title: Means and Methods For Monitoring Protease Inhibitor Antiretroviral Therapy and Guiding Therapeutic Decisions in the Treatment of HIV/AIDS

Inventors: Parkin & Ziermann Filing Date: January 19, 2001

30/30




Fig. 8

This Page is Inserted by IFW Indexing and Scanning Operations and is not part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:
☐ BLACK BORDERS
☐ IMAGE CUT OFF AT TOP, BOTTOM OR SIDES
FADED TEXT OR DRAWING
BLURRED OR ILLEGIBLE TEXT OR DRAWING
☐ SKEWED/SLANTED IMAGES
COLOR OR BLACK AND WHITE PHOTOGRAPHS
☐ GRAY SCALE DOCUMENTS
☐ LINES OR MARKS ON ORIGINAL DOCUMENT
☐ REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY

IMAGES ARE BEST AVAILABLE COPY.

☐ OTHER:

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.